Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

N/ACompletedNCT00927537

Bayer2,052 enrolled

Overview

The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months

Study Type

OBSERVATIONAL

Enrollment

2,052

Conditions

Hypertension

Interventions

Telmisartan (Kinzal/Pritor, BAY68-9291)DRUG

Patients under daily life treatment receiving Kinzal according to local drug information.

Telmisartan (Kinzal/Pritor, BAY68-9291) + HydrochlorothiazideDRUG

Patients under daily life treatment receiving Kinzalplus according to local drug information.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hypertensive patients seen by the physician requiring antihypertensive treatment Exclusion Criteria: * According to the local drug information

Locations (1)

Unnamed facility

Many Locations, Switzerland

Outcomes

Primary Outcomes

Blood pressure

Time frame: After 1-2 weeks, 1month, 3-4 months

Secondary Outcomes

Change in Mean heart rate (bpm)

Time frame: Baseline and 3-4 month

Change in Mean Weight (kg)

Time frame: Baseline and 3-4 month

Change in Mean laboratory parameters (total cholesterol, LDL, HDL, triglyceride, fasting blood glucose)

Time frame: Baseline and 3-4 month

Patient Medical History: Duration of hypertension, Pre-treatment of hypertension, Comorbidities and Concomitant treatment

Time frame: Baseline

Final evaluation of efficacy (very good, good, sufficient, insufficient) and tolerability (very good, good, sufficient, insufficient) of treatment by the physician.

Time frame: After 3-4 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.